New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

2

Vertex Kidney Disease Drug Proves its Worth in Phase II

Vertex Pharmaceuticals reported the company’s Phase II proof-of-concept trial of VX-147 in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS), with the drug hitting a statistically significant and clinically meaningful decrease of 47.6% in the urine protein to creatinine ratio (UPCR) at Week 13 compared to baseline.